CHMI with 3D7 malaria
Phase 1Biologic
CHMI with 3D7 malaria is one of 42 biologic programs targeting Acute Lymphoblastic Leukemia. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
163 competitors in Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Oncovin
Eli LillyPhase 3
Adriamycin
PfizerPhase 3
Oncaspar
SServier
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Elspar
DDutch Childhood Oncology Group
Phase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Fludara
SanofiPhase 3
Iclusig
TakedaPhase 3
Cellcept
RochePhase 3
Neoral
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CHMI with 3D7 malaria. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- LLeiden University Medical Center